Your new experience awaits. Try the new design now and help us make it even better

SYSTEMATIC REVIEW article

Front. Psychol.

Sec. Health Psychology

Volume 16 - 2025 | doi: 10.3389/fpsyg.2025.1673832

This article is part of the Research TopicIntegrating Health Psychology in Practice: Enhancing Well-being and Improving Health Outcomes Across Diverse ContextsView all 27 articles

Prevalence of Stigma Among Patients with Schizophrenia: A Multi-Country Systematic Review and Meta-Analysis

Provisionally accepted
Xianhua  WangXianhua Wang1,2*Jiangli  HuJiangli Hu2Xiaoxia  WangXiaoxia Wang2Jing  LiuJing Liu2Yunqiong  WangYunqiong Wang2
  • 1Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
  • 2Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, China

The final, formatted version of the article will be published soon.

Objective: This study aims to systematically assess the current prevalence of stigma experienced by individuals with schizophrenia and to provide evidence that can inform the development of effective intervention strategies. Methods: A systematic search was conducted in PubMed, Embase, Ovid, Web of Science, Cochrane Library, CINAHL, CNKI, Wanfang, VIP, and CBM databases to identify studies on stigma in schizophrenia patients from their inception up to November 2024. Two independent researchers performed literature screening, data extraction, and quality assessment. Meta-analysis was carried out using Stata 17.0. Results: Fourteen studies encompassing a total of 1,872 schizophrenia patients were included in the analysis. The pooled prevalence of stigma was 75.3% (95%CI : 0.690 −0.816). Subgroup analyses revealed the following rates: Region: Asia 79.6% (95%CI : 0.752 −0.841), Africa 49.9% (95%CI : 0.460−0.538); Assessment tool: PDD 83.9% (95%CI : 0.814−0.864), ISMI 73.9%(95%CI : 0.665 −0.814); Publication year: 2018–2024 year 80.8% (95%CI : 0.737 −0.878), 2014–2017 year 69.7%(95%CI : 0.595 −0.800); Age: >60 years 79.5%(95%CI : 0.767 −0.824), 18–60 years 74.2% (95%CI : 0.662 −0.821); Disease stage: Remission phase 75.8% (95%CI : 0.679 −0.836), Stable phase 74.1% (95%CI : 0.635 −0.848); Sample size: >200 cases 73.4% (95%CI : 0.652 −0.816), ≤ 200 cases 80.2% (95%CI : 0.731 −0.873). Sample size: >200 cases 73.4% (95%CI : 0.652 −0.816), <200 cases 73.4% (95%CI : 0.652 −0.816). SensitivitySSensitivity analysis using the leave-one-out method demonstrated stable pooled effect sizes. Egger's test (P = 0.08) suggested a low risk of publication bias. Conclusion: The prevalence of stigma among individuals with schizophrenia is substantial and influenced by region, assessment instruments, age, stage of illness, and sample size. The subgroup analysis indicated a higher prevalence of stigma associated with the following factors: studies conducted in Asia, the use of the PPD scale, publication after 2018, participants aged > 60 years, Sample size: ≤200 cases and patients in the remission stage. Future efforts should prioritize developing culturally adapted interventions specifically aimed at reducing stigma, enhancing social functioning, and improving patients' quality of life.

Keywords: Schizophrenia, Prevalence, stigma, Meta-analysis, Systematic-review

Received: 26 Jul 2025; Accepted: 17 Oct 2025.

Copyright: © 2025 Wang, Hu, Wang, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xianhua Wang, 1778407464@qq.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.